Inclusion of cost effectiveness in licensing requirements of new drugs: the fourth hurdle.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 15499118.
- Also identified by PMC identifier 524116.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Increasing numbers of countries are considering cost effectiveness in decisions about which drugs to make available for prescription. How do the different approaches work and is it time for standardisation?
Medical subject headings
- Drug Approval
- Drug Costs
- Licensure